BTIG Reiterates Buy Rating on Bicara Therapeutics, Sets $39 Target
BTIG reiterated its Buy rating and $39 price target for Bicara Therapeutics. The target implies 132.4% upside from the Oct. 16 close of $16.78.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.